000100742 001__ 100742
000100742 005__ 20230519145437.0
000100742 0247_ $$2doi$$a10.1016/j.cmi.2021.02.019
000100742 0248_ $$2sideral$$a123405
000100742 037__ $$aART-2021-123405
000100742 041__ $$aeng
000100742 100__ $$aBlanco, J.R.
000100742 245__ $$aPulmonary long-term consequences of COVID-19 infections after hospital discharge
000100742 260__ $$c2021
000100742 5060_ $$aAccess copy available to the general public$$fUnrestricted
000100742 5203_ $$aObjectives: COVID-19 survivors are reporting residual abnormalities after discharge from the hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. The aim of this study was to describe lung function and to identify biomarkers in serum and induced sputum samples from patients recovering from COVID-19 hospitalisation.
Methods: Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by a real-time PCR (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited for this study. Each hospital screened their lists of discharged patients at least 45 days after symptom onset. SARS-CoV-2-infected patients were divided into mild/moderate and severe disease groups according to the severity of their symptoms during hospitalisation. Patients’ epidemiological and medical histories, comorbidities, chronic treatments, and laboratory parameters were evaluated. Pulmonary function tests, the standardised 6-minute walk test (6 MWT) and chest computed tomography (CT) were also performed. The levels of proteases, their inhibitors, and shed receptors were measured in serum and induced sputum samples.
Results: A total of 100 patients with respiratory function tests were included in this study. The median number of days after the onset of symptoms was 104 (IQR 89.25, 126.75). COVID-19 was severe in 47% (47/100) of patients. CT was normal in 48% (48/100) of patients. Lung function was normal (FEV1 ≥80%, FVC ≥80%, FEV1/FVC ≥0.7, and diffusing capacity for carbon monoxide [DLCO] ≥80%) in 92% (92/100), 94% (94/100), 100% (100/100) and 48% (48/100) of patients, respectively. Multivariate analysis showed that a DLCO <80% (OR 5.92; 95%CI 2.28-15.37; p <0.0001) and a lower serum LDH level (OR 0.98; 95%CI 0.97-0.99) were associated with the severe disease group of SARS-CoV-2 during hospital stay.
Conclusions: A diffusion deficit (DLCO <80%) was still present after hospital discharge and was associated with the most severe SARS-CoV-2 cases.
000100742 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/COV20-00401
000100742 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000100742 590__ $$a13.31$$b2021
000100742 592__ $$a3.111$$b2021
000100742 594__ $$a16.5$$b2021
000100742 591__ $$aMICROBIOLOGY$$b13 / 138 = 0.094$$c2021$$dQ1$$eT1
000100742 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000100742 591__ $$aINFECTIOUS DISEASES$$b12 / 96 = 0.125$$c2021$$dQ1$$eT1
000100742 593__ $$aInfectious Diseases$$c2021$$dQ1
000100742 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000100742 700__ $$aCobos-Ceballos, M.J.
000100742 700__ $$aNavarro, F.
000100742 700__ $$0(orcid)0000-0003-1436-4334$$aSanjoaquin, I.$$uUniversidad de Zaragoza
000100742 700__ $$aArnaiz de las Revillas, F.
000100742 700__ $$aBernal, E.
000100742 700__ $$aBuzon-Martin, L.
000100742 700__ $$aViribay, M.
000100742 700__ $$aRomero, L.
000100742 700__ $$aEspejo-Pérez, S.
000100742 700__ $$aValencia, B.
000100742 700__ $$aIbañez, D.$$uUniversidad de Zaragoza
000100742 700__ $$aFerrer-Pargada, D.
000100742 700__ $$aMalia, D.
000100742 700__ $$aGutierrez-Herrero, F.G.
000100742 700__ $$aOlalla, J.
000100742 700__ $$aJurado-Gamez, B.
000100742 700__ $$aUgedo, J.
000100742 7102_ $$11011$$2770$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Radiol. y Medicina Física
000100742 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000100742 773__ $$g27 (2021), 892 - 896$$pClin. microbiol. infect.$$tClinical Microbiology and Infection$$x1198-743X
000100742 8564_ $$s320513$$uhttps://zaguan.unizar.es/record/100742/files/texto_completo.pdf$$yPostprint
000100742 8564_ $$s1289790$$uhttps://zaguan.unizar.es/record/100742/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000100742 909CO $$ooai:zaguan.unizar.es:100742$$particulos$$pdriver
000100742 951__ $$a2023-05-18-14:24:42
000100742 980__ $$aARTICLE